2020
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation
Małyszko J, Bamias A, Danesh F, Dębska-Ślizień A, Gallieni M, Gertz M, Kielstein J, Tesarova P, Wong G, Cheung M, Wheeler D, Winkelmayer W, Porta C, Participants C, Abu-Alfa A, Amer H, Beutel G, Chapman J, Chen X, Chudek J, Cosmai L, Danesi R, De Stefano F, Iseki K, Jaimes E, Jhaveri K, Jurczyszyn A, Kazancioğlu R, Kitchlu A, Kollmannsberger C, Lahoti A, Li Y, Macía M, Matsubara T, Mitropoulos D, Noiri E, Perazella M, Ronco P, Rosner M, Romeo M, Sprangers B, Stadler W, Stevens P, Tesař V, da Costa e Silva V, Vesole D, Vijayan A, Viklický O, Workeneh B, Yanagita M, Zakharova E. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International 2020, 98: 1407-1418. PMID: 33276867, DOI: 10.1016/j.kint.2020.07.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseHematological malignanciesControversies ConferenceKidney transplantationModerate stage chronic kidney diseaseKDIGO Controversies ConferenceAcute kidney injuryKidney transplant recipientsBurden of cancerKidney injuryTransplant recipientsKidney transplantRegistry analysisMultiple myelomaClinical challengeCancer riskGlobal outcomeMalignancyCancerPatientsDiseaseTransplantationBidirectional relationshipRiskFramework for establishing integrated kidney care programs in low- and middle-income countries
Tonelli M, Nkunu V, Varghese C, Abu-Alfa AK, Alrukhaimi MN, Bernieh B, Fox L, Gill J, Harris D, Hou F, O’Connell P, Rashid H, Niang A, Ossareh S, Tesar V, Zakharova E, Yang C. Framework for establishing integrated kidney care programs in low- and middle-income countries. Kidney International Supplements 2020, 10: e19-e23. PMID: 32149006, PMCID: PMC7031683, DOI: 10.1016/j.kisu.2019.11.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic kidney diseaseKidney care programKidney replacement therapyKidney failureKidney diseaseKidney careMiddle-income countriesReplacement therapyCare programAcute kidney injuryUrgent public health needPublic health needsKidney injuryKidney transplantationPrimary preventionPreventive careRisk factorsNoncommunicable diseasesTimely managementKidney disordersHealth needsMild formHealth systemDiseaseTherapy
2013
Acute Kidney Injury and Bisphosphonate Use in Cancer: A Report From the Research on Adverse Drug Events and Reports (RADAR) Project
Edwards BJ, Usmani S, Raisch DW, McKoy JM, Samaras AT, Belknap SM, Trifilio SM, Hahr A, Bunta AD, Abu-Alfa A, Langman CB, Rosen ST, West DP. Acute Kidney Injury and Bisphosphonate Use in Cancer: A Report From the Research on Adverse Drug Events and Reports (RADAR) Project. JCO Oncology Practice 2013, 9: 101-106. PMID: 23814519, PMCID: PMC3595436, DOI: 10.1200/jop.2011.000486.Peer-Reviewed Original ResearchConceptsAcute kidney injuryZoledronic acidKidney injuryAdverse eventsProportional reporting ratioFDA AERSBisphosphonate useSafety signalsReporting ratioAdverse drug eventsDrug Administration adverse eventsAdverse drug reactionsCancer clinical trialsPremorbid diseaseRenal injuryRenal problemsMean ageMultiple myelomaDrug eventsDrug reactionsClinical trialsProstate cancerBreast cancerCancer settingUS Food
2011
Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment
2010
Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and Management
Abu-Alfa AK, Younes A. Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and Management. American Journal Of Kidney Diseases 2010, 55: s1-s13. PMID: 20420966, DOI: 10.1053/j.ajkd.2009.10.056.BooksConceptsTumor lysis syndromeAcute kidney injuryKidney injuryLysis syndromeKidney functionRisk factorsClinical tumor lysis syndromePatient-specific risk factorsPatient's kidney functionMassive tumor cell deathSerious clinical complicationsIdentification of tumorsTumor cell deathCardiac arrestClinical complicationsEarly recognitionClinical abnormalitiesEfficacious interventionsSecondary hypocalcemiaInjurySyndromeCell deathHypocalcemiaHyperkalemiaHyperphosphatemia
2008
The Impact of NSF on the Care of Patients With Kidney Disease
Abu-Alfa A. The Impact of NSF on the Care of Patients With Kidney Disease. Journal Of The American College Of Radiology 2008, 5: 45-52. PMID: 18180009, DOI: 10.1016/j.jacr.2007.08.018.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic kidney diseaseNephrogenic systemic fibrosisGlomerular filtration rateCare of patientsGadolinium-based magnetic resonance contrast agentsRenal diseasePeritoneal dialysisKidney diseaseFiltration rateSystemic fibrosisStage 4 chronic kidney diseaseCases of NSFNormal glomerular filtration rateAcute kidney injurySessions of hemodialysisMajority of casesCKD patientsKidney injuryMagnetic resonance contrast agentsSignificant morbidityPD patientsVascular accessProlonged eliminationOdds ratio